Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10

Authors :: Robert B. Livingston
L. Seymour
Barbara Graham
Timothy Winton
Marlo Whitehead
Keyue Ding
James R. Rigas
Frances A. Shepherd
David H. Johnson
I. Gauthier
Source :: Journal of Clinical Oncology. 23:7200-7200
Publication Year :: 2005
Publisher :: American Society of Clinical Oncology (ASCO), 2005.
Abstract: 7200 Background: Cisplatin ACT induced anemia may correlate with adverse events (AEs), poor Quality of Life (QoL), inability to deliver ACT, relapse free survival (RFS) or overall survival (OS). Me...

Subjects :: Cisplatin
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Anemia
Adjuvant chemotherapy
non-small cell lung cancer (NSCLC)
medicine.disease
Internal medicine
medicine
In patient
Hemoglobin hb
business
Adverse effect
medicine.drug
Cisplatin/vinorelbine

Full Text Access

Tools